Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial
Titel:
Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial
Auteur:
Kumar, Shaji K Jacobus, Susanna J Cohen, Adam D Weiss, Matthias Callander, Natalie Singh, Avina K Parker, Terri L Menter, Alexander Yang, Xuezhong Parsons, Benjamin Kumar, Pankaj Kapoor, Prashant Rosenberg, Aaron Zonder, Jeffrey A Faber Jr, Edward Lonial, Sagar Anderson, Kenneth C Richardson, Paul G Orlowski, Robert Z Wagner, Lynne I Rajkumar, S Vincent